Nkarta Inc (NASDAQ: NKTX) received FDA clearance for its Investigational New Drug (IND) application to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate,
Gamida Cell Ltd (NASDAQ: GMDA) released new early data in 10 patients with CD20-positive non-Hodgkin lymphoma enrolled in the first three cohorts in an ongoing Phase 1 study of natural killer (NK)
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant
Alignment Healthcare Inc (NASDAQ: ALHC) announced that its California Medicare Advantage (MA) HMO – which represents roughly 89% of its MA membership – has maintained an overall 4 out of 5-star rating from the Centers for Medicare & Medicaid Services (CMS) for 2024, marking its seventh
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit